[go: up one dir, main page]

PE20190180A1 - Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas - Google Patents

Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas

Info

Publication number
PE20190180A1
PE20190180A1 PE2018003204A PE2018003204A PE20190180A1 PE 20190180 A1 PE20190180 A1 PE 20190180A1 PE 2018003204 A PE2018003204 A PE 2018003204A PE 2018003204 A PE2018003204 A PE 2018003204A PE 20190180 A1 PE20190180 A1 PE 20190180A1
Authority
PE
Peru
Prior art keywords
formula
compound
chf2
fluoro
reacts
Prior art date
Application number
PE2018003204A
Other languages
English (en)
Inventor
Peter Fey
Donald Bierer
Alfons Grunenberg
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47222101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190180(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of PE20190180A1 publication Critical patent/PE20190180A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63Esters of sulfonic acids
    • C07C309/64Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/02Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/04Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/023Preparation; Separation; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/037Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/067Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se refiere a un procedimiento para preparar aldehidos de formula H-CO-CF=CH-NR1R2 (Formula III) que comprende hacer reaccionar anhidrido trifluorometanosulfonico con 2,2,3,3-tetrafluoro-1-propanol sin disolvente y se hace reaccionar el resultante trifluorometanosulfonato de 2,2,3,3-tetrafluoropropilo con un compuesto de formula R2-NH-R1 (Formula XIIa) para obtener un compuesto de formula NR1R2-CH2-CF2-CHF2 (Formula XIIIa), que luego reacciona con metanosulfonato de metilo para obtener un compuesto de formula N+R1R2(CH3)-CH2-CF2-CHF2 CH3SO3- (Formula XIVa), que luego reacciona con hidroxido de sodio para obtener un compuesto de formula N+R1R2(CH3)-CH2=CF-CHF2 CH3SO3- (Formula XVa), que reacciona finalmente con un compuesto de formula XIIa para obtener el compuesto de formula (III), donde R1 y R2 son metilo, etilo, isopropilo, fenilo, entre otros. Tambien esta referida a un procedimiento de preparacion del compuesto de formula (2Z)-2-fluoro-3-morfolin-4-ilacrilaldehido (Formula IIIa)
PE2018003204A 2011-11-25 2012-11-21 Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas PE20190180A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190789 2011-11-25
EP11192301 2011-12-07
PCT/EP2012/073276 WO2013076168A1 (de) 2011-11-25 2012-11-21 Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen

Publications (1)

Publication Number Publication Date
PE20190180A1 true PE20190180A1 (es) 2019-02-01

Family

ID=47222101

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2018003204A PE20190180A1 (es) 2011-11-25 2012-11-21 Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
PE2018003205A PE20190181A1 (es) 2011-11-25 2012-11-21 Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
PE2014000713A PE20142359A1 (es) 2011-11-25 2012-11-21 Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2018003205A PE20190181A1 (es) 2011-11-25 2012-11-21 Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
PE2014000713A PE20142359A1 (es) 2011-11-25 2012-11-21 Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas

Country Status (41)

Country Link
US (7) US8802847B2 (es)
EP (3) EP3421470B8 (es)
JP (4) JP6189315B2 (es)
KR (3) KR101943788B1 (es)
CN (3) CN105503867B (es)
AP (2) AP3898A (es)
AR (1) AR088983A1 (es)
AU (3) AU2012342547C1 (es)
BR (2) BR122020001312B1 (es)
CA (2) CA2856706C (es)
CL (2) CL2014001339A1 (es)
CO (1) CO6960555A2 (es)
CR (3) CR20190057A (es)
CU (3) CU24354B1 (es)
CY (1) CY1124000T1 (es)
DK (3) DK2896617T3 (es)
DO (3) DOP2014000112A (es)
EA (4) EA033455B1 (es)
EC (1) ECSP14001627A (es)
ES (3) ES2603028T3 (es)
GT (1) GT201400101A (es)
HR (3) HRP20181818T1 (es)
HU (3) HUE053745T2 (es)
IL (3) IL232585A0 (es)
JO (3) JOP20120351B1 (es)
LT (3) LT2782914T (es)
MX (2) MX357481B (es)
MY (3) MY198086A (es)
PE (3) PE20190180A1 (es)
PH (2) PH12014501160A1 (es)
PL (3) PL3421470T3 (es)
PT (3) PT2896617T (es)
RS (3) RS61609B1 (es)
SG (3) SG10201604196VA (es)
SI (3) SI2896617T1 (es)
TR (1) TR201816203T4 (es)
TW (5) TWI659016B (es)
UA (3) UA120278C2 (es)
UY (2) UY34467A (es)
WO (1) WO2013076168A1 (es)
ZA (2) ZA201403613B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
CU24354B1 (es) 2011-11-25 2018-08-06 Adverio Pharma Gmbh Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
JP6386478B2 (ja) 2013-02-21 2018-09-05 アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング メチル{4,6−ジアミノ−2−[1−(2−フルオロベンジル)−1h−ピラゾロ[3,4−b]ピリジノ−3−イル]ピリミジノ−5−イル}メチルカルバメートの形態
JO3318B1 (ar) 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
MX2018007152A (es) 2015-12-14 2018-08-15 Ironwood Pharmaceuticals Inc Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal.
US20190381039A1 (en) 2016-12-13 2019-12-19 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
ES2924359T3 (es) 2017-04-11 2022-10-06 Sunshine Lake Pharma Co Ltd Compuestos de indazol sustituidos con flúor y usos de los mismos
BR112021000358A2 (pt) 2018-07-11 2021-04-06 Cyclerion Therapeutics, Inc. Uso de estimulantes de sgc para o tratamento de distúrbios mitocondriais
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
CA3127128A1 (en) * 2019-01-22 2020-07-30 Adverio Pharma Gmbh Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine
CN115175666B (zh) * 2020-02-03 2024-04-26 阿德弗里奥药品有限责任公司 {4,6-二氨基-2-[5-氟-1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}氨基甲酸甲酯的纳米制剂
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
US20240352014A1 (en) 2021-08-31 2024-10-24 Teva Pharmaceuticals International Gmbh Solid state forms of vericiguat and process for preparation thereof
ES2956054B2 (es) 2022-05-03 2024-07-01 Moehs Iberica Sl 2-(5-FLUORO-1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL)-5-NITROSOPIRIMIDIN-4,6-DIAMINA O UNA SAL DE LA MISMA, PROCEDIMIENTO PARA SU PREPARACION Y SU USO EN LA SINTESIS DE VERICIGUAT
CN115043835B (zh) * 2022-06-17 2023-05-09 常州制药厂有限公司 一种维立西呱的精制纯化方法
WO2024038398A1 (en) * 2022-08-18 2024-02-22 Torrent Pharmaceuticals Limited Novel salt of substituted 5-fluoro-1h-pyrazolopyridines and its uses
WO2025114276A1 (en) 2023-12-01 2025-06-05 Krka, D.D., Novo Mesto Solid oral composition comprising vericiguat
WO2025132065A1 (en) 2023-12-20 2025-06-26 Adverio Pharma Gmbh Dose regimen for vericiguat
CN117924280B (zh) * 2024-03-20 2024-07-12 中国人民解放军军事科学院军事医学研究院 取代噻吩基-5-氟-1h-吡唑并吡啶类化合物及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8606936D0 (en) * 1986-03-20 1986-04-23 Ici Plc Organic compounds
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
HUP0001115A3 (en) 1996-10-14 2001-06-28 Bayer Ag Heterocyclylmethyl-substituted pyrazol derivatives, process for their preparation and pharmaceuticals containing the same
US6451805B1 (en) 1997-11-14 2002-09-17 Bayer Aktiengesellschaft Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE59906902D1 (de) * 1998-11-16 2003-10-09 Basf Ag Herbizide 3-(benzo(ox/thi)azol-7-yl)-1h-pyrimidin-2,4-dione
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE10131987A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Pyridin-substituierte Pyrazolopyridinderivate
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
WO2002042299A1 (de) 2000-11-22 2002-05-30 Bayer Aktiengesellschaft Neue lactam-substituierte pyrazolopyridinderivate
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
KR100971616B1 (ko) 2001-06-22 2010-07-22 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물
DE10132416A1 (de) 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10222550A1 (de) 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DE10232571A1 (de) 2002-07-18 2004-02-05 Bayer Ag 4-Aminosubstituierte Pyrimidinderivate
DE10232572A1 (de) 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10351903A1 (de) 2003-11-06 2005-06-09 Bayer Healthcare Ag Neue Kombination
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006031175A1 (de) 2006-07-06 2008-01-10 Bayer Healthcare Ag Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
WO2009000832A2 (en) 2007-06-25 2008-12-31 Boehringer Ingelheim International Gmbh Chemical compounds
AR067762A1 (es) 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
JP2011513483A (ja) 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
KR100979460B1 (ko) * 2008-05-13 2010-09-02 한국과학기술연구원 함불소알킬그룹이 치환된 이온성 액체의 직접 제조방법
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
KR101861981B1 (ko) 2009-11-27 2018-05-28 아드베리오 파마 게엠베하 제약상 물질로서 사용하기 위한 메틸-(4,6-디아미노-2-(1-(2-플루오로벤질)-1h-피라졸로(3,4-b)피리디노-3-일)피리미디노-5-일)메틸카르바메이트의 제조 방법 및 그의 정제
UY33040A (es) * 2009-11-27 2011-06-30 Bayer Schering Pahrma Akitengesellschaft Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
UY33041A (es) * 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PH12013500055A1 (en) 2010-07-09 2017-08-23 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040234A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril
DE102010040233A1 (de) * 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
JP6054967B2 (ja) 2011-09-02 2016-12-27 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換アネレート化ピリミジンおよびその使用
CU24354B1 (es) * 2011-11-25 2018-08-06 Adverio Pharma Gmbh Procedimiento de obtención de derivados de tetrafluoropropilmorfolina

Also Published As

Publication number Publication date
EP2896617A1 (de) 2015-07-22
KR20170130612A (ko) 2017-11-28
PE20190181A1 (es) 2019-02-01
UA120278C2 (uk) 2019-11-11
US8802847B2 (en) 2014-08-12
JP6392436B2 (ja) 2018-09-19
JOP20210064A1 (ar) 2023-01-30
TWI665198B (zh) 2019-07-11
LT2782914T (lt) 2018-10-10
EA201690521A1 (ru) 2016-06-30
MX2014006018A (es) 2014-06-04
US20140315926A1 (en) 2014-10-23
HUE053745T2 (hu) 2021-07-28
IL246265B (en) 2018-12-31
CR20140237A (es) 2014-06-19
CN105503867B (zh) 2019-01-11
PE20142359A1 (es) 2015-01-09
JP2015502932A (ja) 2015-01-29
JP2018199698A (ja) 2018-12-20
ES2603028T8 (es) 2021-12-29
SG10201604192XA (en) 2016-07-28
AU2017254916B2 (en) 2019-02-28
CA2856706A1 (en) 2013-05-30
CR20190057A (es) 2019-04-23
ECSP14001627A (es) 2015-11-30
US10633356B2 (en) 2020-04-28
SG11201402111QA (en) 2014-08-28
ZA201403613B (en) 2016-02-24
CA3040720A1 (en) 2013-05-30
TR201816203T4 (tr) 2018-11-21
IL246265A0 (en) 2016-07-31
JOP20210065A1 (ar) 2023-01-30
IL263389B (en) 2022-03-01
IL263389A (en) 2018-12-31
PT3421470T (pt) 2021-03-31
US20190177287A1 (en) 2019-06-13
ES2603028T3 (es) 2017-02-23
TW201831447A (zh) 2018-09-01
AU2012342547B2 (en) 2017-08-17
KR20190018021A (ko) 2019-02-20
CN106905314A (zh) 2017-06-30
CU24257B1 (es) 2017-05-10
LT3421470T (lt) 2021-04-26
EA201491028A1 (ru) 2014-12-30
CU20150124A7 (es) 2016-03-31
AU2012342547C1 (en) 2019-02-21
AU2019202123B2 (en) 2020-09-24
SI2896617T1 (sl) 2016-12-30
US9604948B2 (en) 2017-03-28
NZ721592A (en) 2018-02-23
PT2782914T (pt) 2018-11-16
BR112014012414B1 (pt) 2022-01-11
CN105503867A (zh) 2016-04-20
MX357481B (es) 2018-07-11
PH12015501494A1 (en) 2015-09-07
PH12014501160B1 (en) 2014-10-20
EP2782914A1 (de) 2014-10-01
CL2016000344A1 (es) 2017-02-10
PL3421470T3 (pl) 2021-08-02
CU24354B1 (es) 2018-08-06
UA116623C2 (uk) 2018-04-25
AR088983A1 (es) 2014-07-23
AP2015008243A0 (en) 2015-01-31
DOP2014000112A (es) 2014-07-15
US20160009671A1 (en) 2016-01-14
EP2782914B1 (de) 2018-08-01
AU2017254916A1 (en) 2017-11-23
CN104159898A (zh) 2014-11-19
JOP20120351B1 (ar) 2021-08-17
JP2018058860A (ja) 2018-04-12
DOP2017000013A (es) 2017-02-15
ES2694158T3 (es) 2018-12-18
HUE041592T2 (hu) 2019-05-28
BR122020001312B1 (pt) 2022-02-15
JP6340391B2 (ja) 2018-06-06
DK3421470T3 (da) 2021-04-06
EA201690520A1 (ru) 2016-07-29
HRP20161501T1 (hr) 2016-12-16
ES2864009T3 (es) 2021-10-13
JP2017031180A (ja) 2017-02-09
KR102026059B1 (ko) 2019-09-26
UY34467A (es) 2013-06-28
NZ624593A (en) 2016-10-28
CN104159898B (zh) 2017-01-18
EP3421470B1 (de) 2021-01-20
AP3898A (en) 2016-11-16
RS61609B1 (sr) 2021-04-29
ZA201505970B (en) 2017-08-30
CA2856706C (en) 2020-06-16
RS55387B1 (sr) 2017-03-31
CL2014001339A1 (es) 2014-10-17
CY1124000T1 (el) 2022-05-27
US20170158652A1 (en) 2017-06-08
MY198086A (en) 2023-07-31
CA3040720C (en) 2021-06-15
MY168412A (en) 2018-11-09
PH12015501494B1 (en) 2015-09-07
PT2896617T (pt) 2016-11-18
BR112014012414A2 (pt) 2017-06-06
EA031602B1 (ru) 2019-01-31
RS57945B1 (sr) 2019-01-31
TW201932465A (zh) 2019-08-16
AU2019202123A1 (en) 2019-04-18
EA201892050A1 (ru) 2019-02-28
US10633357B2 (en) 2020-04-28
LT2896617T (lt) 2016-12-12
DK2782914T3 (en) 2018-11-26
GT201400101A (es) 2014-11-13
HK1223613A1 (zh) 2017-08-04
JP6189315B2 (ja) 2017-08-30
EP3421470B8 (de) 2021-08-11
BR112014012414A8 (pt) 2018-01-23
PL2896617T3 (pl) 2017-07-31
US10364229B2 (en) 2019-07-30
US20190177288A1 (en) 2019-06-13
HK1203951A1 (en) 2015-11-06
EP2896617B1 (de) 2016-10-05
CR20210072A (es) 2021-03-22
WO2013076168A1 (de) 2013-05-30
HUE031029T2 (en) 2017-06-28
EP3421470A1 (de) 2019-01-02
TWI631123B (zh) 2018-08-01
UY39646A (es) 2022-04-29
NZ724215A (en) 2018-03-23
US9150573B2 (en) 2015-10-06
TW201838993A (zh) 2018-11-01
DK2896617T3 (en) 2016-12-12
DOP2021000179A (es) 2021-09-30
KR101993022B1 (ko) 2019-06-25
KR20140105483A (ko) 2014-09-01
CU20150123A7 (es) 2016-03-31
TW201329076A (zh) 2013-07-16
AU2012342547A1 (en) 2014-06-05
EA030018B1 (ru) 2018-06-29
CO6960555A2 (es) 2014-05-30
HRP20210507T1 (hr) 2021-05-28
US9845300B2 (en) 2017-12-19
TW201708219A (zh) 2017-03-01
SI2782914T1 (sl) 2018-12-31
MX375872B (es) 2025-03-07
AP2014007705A0 (en) 2014-06-30
HRP20181818T1 (hr) 2019-01-11
CU20140055A7 (es) 2014-10-02
TWI597280B (zh) 2017-09-01
TWI659016B (zh) 2019-05-11
EA201491028A8 (ru) 2016-01-29
SI3421470T1 (sl) 2021-07-30
UA119269C2 (uk) 2019-05-27
PH12014501160A1 (en) 2014-10-20
US20130143900A1 (en) 2013-06-06
KR101943788B1 (ko) 2019-01-29
MY197904A (en) 2023-07-24
PL2782914T3 (pl) 2019-01-31
IL232585A0 (en) 2014-06-30
SG10201604196VA (en) 2016-07-28
EA033455B1 (ru) 2019-10-31
US20180065942A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
PE20190180A1 (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
AR114631A1 (es) Métodos e intermedios para preparar compuestos de piridina
BR112015017869A2 (pt) hidroalquilação aromtática de alquilo para a produção de plastificantes
PE20121350A1 (es) Metodos sinteticos para compuestos espiro-oxoindol
BR112012008939A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt2
AR116790A1 (es) PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA)
BR112014030365A2 (pt) síntese de composto antiviral
AR072447A1 (es) Proceso para preparar 2- alcoximetilen-4,4-difluoro-3-oxobutiratos de alquilo
AR117002A2 (es) Proceso para la preparación de inhibidores de quinasa c-fms
MX337320B (es) Análogos halogenados de agentes anti-fibroticos.
AR094948A1 (es) Preparación de haloalcoxiarilhidracinas y los intermediarios a partir de los mismos
AR098002A1 (es) Preparación de derivados hidroxi-bencilbenceno
IN2012DN01815A (es)
ES2603227T3 (es) Proceso para la preparación de compuestos cetólidos
CR20170134A (es) Método para preparar 2´-o-fucosil-lactosa
AR105091A1 (es) Procedimiento para la síntesis de derivados de rapamicina
AR098200A1 (es) Proceso para preparar aluminoxanos, componente catalizador y aluminoxano resultantes
MX2015013531A (es) Alquil glicosidos como surfactantes.
IN2014CN04960A (es)
CO6700138A1 (es) Procedimiento de preparación de sal de l-arginina de perindoprilo
MX2018014130A (es) Procedimiento e intermedios para la 6,7-alfa-epoxidacion de 4,6-dienos esteroideos.
MX2014002761A (es) Compuestos reguladores del crecimiento vegetal.
MX2019000105A (es) Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble.
MX2020009462A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.
CL2019002795A1 (es) Proceso para preparar 2-exo-(2-metilbenciloxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano.